Monkey Anti-anti-HBsAg IgG ELISA kit

Sample

Serum, Plasma

Species Reactivity

Monkey

Detection Method

iELISA

Intended Use

The Monkey Anti-HBsAg IgG ELISA Kit detects and quantifies HBsAg (hepatitis B surface antigen) IgG in monkey serum or plasma of vaccinated, immunized and/or infected hosts. This immunoassay is suitable for:
1. Determining immune status relative to non-immune controls;
2. Assessing efficacy of vaccines, including dosage, adjuvantcy, route of immunization and timing;
3. Qualifying and/or standardizing vaccine batches and protocols.
For research use only (RUO), not for diagnostic use.

Contents of Kit

1. Wash Solution Concentrate (100×), 10ml
2. Sample Diluent Concentrate (20×), 10ml
3. Anti-Monkey IgG-HRP Conjugate Concentrate (100×), 0.15ml
4. HBsAg Microwell Strip Plate, 8-well strips (12). Coated with recombinant HBsAg, and post-coated with stabilizers.
5. Anti-HBsAg Calibrators: 0.65 ml/each. 10 U/ml / 25 U/ml / 50 U/ml / 100 U/ml. Four (4) vials, each containing anti-HBsAg in arbitrary activity Units; diluted in buffer with protein, detergents and antimicrobial.
6. Anti-HbsAg Positive Control: 0.65ml. Anti-HbsAg IgG, diluted in buffer with protein, detergents and antimicrobial as stabilizers. Net OD > 0.5.
7. Low NSB Sample Diluent: 30 ml. Buffer with protein, detergents and antimicrobial as stabilizers. Use as is for sample dilution.
8. TMB Substrate: 12 ml. Chromogenic substrate for HRP containing TMB and peroxide.
9. Stop Solution: 12 ml. Dilute sulfuric acid.

Storage

The microtiter well plate and all other reagents, if unopened, are stable at 2-8°C until the expiration date printed on the box label.

General Description

Hepatitis B is an infectious disease caused by hepatitis B virus (HBV). Hepatitis, the acute illness, inflames the liver, causing jaundice, vomiting and (rarely) death. Chronic hepatitis B, however, can cause cirrhosis and liver cancer – a fatal disease. Although viral replication occurs in the liver, HBV spreads to the blood where virus-specific antigens and antibodies may be found in the infected host. Blood tests for these antigens and antibodies are used to diagnose the infection. Acute and chronic hepatitis B can be prevented by vaccination.
HBV is divided into four major serotypes (adr, adw, ayr, ayw) based on antigenic epitopes presented on its envelope proteins, and into eight genotypes (A-H) according to overall nucleotide sequence variation of the genome. Genotypes differ by at least 8% of their sequences, differences which affect severity of disease and response to treatment and possibly vaccination. The hepatitis B surface antigen (HBsAg) is the first detectable viral antigen to appear during infection, and is most frequently used to screen for the presence of infection. HBsAg is also the basis for several recent vaccines, which use synthetic recombinant HBsAg and contain no blood products. Therefore, they cannot cause HBV infection, a problem with the original vaccine prepared from plasma from patients with long-term HBV infection. Following vaccination, HBsAg may be detected in serum for several days. These vaccines have provided protection for 85-90% of individuals. HBV Vaccine common brands available are: Engerix-B (GSK), Elovac B (Human Biologicals Institute, A division of Indian Immunologicals Limited), Genevac B (Serum Institute), Shanvac B etc. These vaccines are given intramuscularly.

General Notes

Hepatitis B is an infectious disease caused by hepatitis B virus (HBV). Hepatitis, the acute illness, inflames the liver, causing jaundice, vomiting and (rarely) death. Chronic hepatitis B, however, can cause cirrhosis and liver cancer – a fatal disease. Although viral replication occurs in the liver, HBV spreads to the blood where virus-specific antigens and antibodies may be found in the infected host. Blood tests for these antigens and antibodies are used to diagnose the infection. Acute and chronic hepatitis B can be prevented by vaccination.
HBV is divided into four major serotypes (adr, adw, ayr, ayw) based on antigenic epitopes presented on its envelope proteins, and into eight genotypes (A-H) according to overall nucleotide sequence variation of the genome. Genotypes differ by at least 8% of their sequences, differences which affect severity of disease and response to treatment and possibly vaccination. The hepatitis B surface antigen (HBsAg) is the first detectable viral antigen to appear during infection, and is most frequently used to screen for the presence of infection. HBsAg is also the basis for several recent vaccines, which use synthetic recombinant HBsAg and contain no blood products. Therefore, they cannot cause HBV infection, a problem with the original vaccine prepared from plasma from patients with long-term HBV infection. Following vaccination, HBsAg may be detected in serum for several days. These vaccines have provided protection for 85-90% of individuals. HBV Vaccine common brands available are: Engerix-B (GSK), Elovac B (Human Biologicals Institute, A division of Indian Immunologicals Limited), Genevac B (Serum Institute), Shanvac B etc. These vaccines are given intramuscularly.